Начало・Списък с акции・Denali Therapeutics Inc

Denali Therapeutics Inc

Затворен

СекторЗдравеопазване

24.31 0.54

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

23.88

Максимум

24.52

Ключови измерители
By Trading Economics
Приходи	102K -128M
EPS	-0.69
Служители	507
EBITDA	-937K -126M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+44.44% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	712M 3.7B
Предишно отваряне	23.77
Предишно затваряне	24.31

Настроения в новините

By Acuity

28%

72%

105 / 340 Класиране в Healthcare

Denali Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:46 ч. UTC

Correlated Moves

News

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

31.07.2026 г., 20:02 ч. UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

30.07.2026 г., 19:18 ч. UTC

Correlated Moves

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

29.07.2026 г., 22:01 ч. UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

28.07.2026 г., 18:46 ч. UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

27.07.2026 г., 19:56 ч. UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

24.07.2026 г., 19:26 ч. UTC

Correlated Moves

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

22.07.2026 г., 17:46 ч. UTC

Correlated Moves

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

21.07.2026 г., 17:36 ч. UTC

Correlated Moves

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

20.07.2026 г., 23:41 ч. UTC

Correlated Moves

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Denali Therapeutics Inc Прогноза

Ценова цел

By TipRanks

44.44% нагоре

12-месечна прогноза

Среден 34.91 USD 44.44%

Висок 42 USD

Нисък 25 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Denali Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Denali Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

105 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.